Drug
TQ-B3101
TQ-B3101 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Other(3)
Detailed Status
unknown3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
unknown375%
completed125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects
NCT04804904
unknownphase_2
A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
NCT04412564
unknownphase_2
Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
NCT03972189
unknownphase_1
A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics
NCT03019276
Clinical Trials (4)
Showing 4 of 4 trials
NCT04804904Phase 1
A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects
NCT04412564Phase 2
A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
NCT03972189Phase 2
Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
NCT03019276Phase 1
A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4